Primary Sclerosing Cholangitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Sclerosing Cholangitis - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Primary Sclerosing Cholangitis (Gastrointestinal) pipeline landscape.
Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by a progressive course of cholestasis with inflammation and fibrosis of the intrahepatic and extra hepatic bile ducts. Symptoms include abdominal pain, chills, diarrhea, fatigue, itchiness, and weight loss. The predisposing factors include age and inflammatory bowel diseases. Treatment includes antibiotics and bile-acid-binding drugs.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Primary Sclerosing Cholangitis - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Primary Sclerosing Cholangitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Primary Sclerosing Cholangitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Primary Sclerosing Cholangitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 13, 6, 2, 11 and 3 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.
Primary Sclerosing Cholangitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Companies Mentioned
Companies Mentioned
AbbVie Inc
Albireo Pharma Inc
Avolynt Inc
BiomX Inc
Cadila Healthcare Ltd
Cascade Pharmaceuticals Inc
Chemomab Therapeutics Ltd
CymaBay Therapeutics Inc
Dr. Falk Pharma GmbH
Emergent Biotechnologies LLC
Engitix Ltd
Escient Pharmaceuticals Inc
Gilead Sciences Inc
Hanmi Pharmaceuticals Co Ltd
HighTide Therapeutics Inc
Iltoo Pharma
Immunic Inc
Intercept Pharmaceuticals Inc
LISCure Biosciences Co Ltd
Mirum Pharmaceuticals Inc
NGM Biopharmaceuticals Inc
Orbsen Therapeutics Ltd
Parvus Therapeutics Inc
Pliant Therapeutics Inc
Qing Bile Therapeutics Inc
Scohia Pharma Inc
Sirnaomics Inc
Takeda Pharmaceutical Co Ltd
Yungjin Pharm Co Ltd
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook